PRESS RELEASE: Forging a Quantum-Secure Future - SSH Communications Security Joins NIST PQC Migration Consortium
Helsinki, Finland – September 1, 2023 –Leading Defensive Cybersecurity Company SSH Communications Security has become part of the US National Institute of Standards and Technology (NIST) Post-Quantum Cryptography Building Block Consortium, operated by the National Cybersecurity Center of Excellence (NCCoE), which is a collaborative hub within NIST that works with industry, government, and academia to address cybersecurity challenges. This innovative collaboration paves the way for quantum-safe solutions in the United States and beyond.
The mission of the Consortium is to bring awareness to the issues involved in migrating to post-quantum algorithms and to develop practices to ease migration from current public-key algorithms to replacement algorithms. NIST does not evaluate commercial products under this Consortium and does not endorse any product or service used.
The collaborative research and development agreement CRADA (National cybersecurity center of excellence migration to post-quantum cryptography building block consortium cooperative research and development agreement) has been officially signed by SSH Communications Security and NIST, solidifying the partnership between the two organizations. The agreement was signed on July 31, 2023, marking the company's official inclusion in the NIST PQC migration consortium.
NIST PQC Algorithm Competition Yields FIPS Standards for Quantum-Safe Algorithms
In response to the critical need for enhanced cybersecurity against quantum threats, NIST published the first FIPS draft of the preferred PQC algorithms, including CRYSTALS-KYBER and CRYSTALS-DILITHIUM, on August 24, 2023. These algorithms were already selected for standardization last year and are expected to be finalized in 2024. SSH Communications Security welcomes the standardization and is particularly enthusiastic about the wider adoption of CRYSTALS-KYBER Key Encapsulation Mechanism (KEM) and future migration to the preferred PQC signature algorithms.
“The retroactive attacks on key exchange in network communication protocols like TLS, SSH, and IPsec require migration to PQC urgently in a safe manner to protect the key agreement from the quantum threat,” says SSH Fellow Ms. SuviLampila. "We are pleased to contribute to the NIST PQC migration effort and also looking forward to the next step of migrating to quantum-safe signature algorithms that require even more industry-wide effort,” Lampila concludes.
Pioneering Quantum-Safe Solutions
With a rich heritage spanning more than 28 years in encryption expertise, SSH Communications Security's participation in the NIST PQC migration consortium marks an important milestone in its journey toward securing the digital landscape against quantum threats.
"I am immensely proud that SSH Communications Security stands at the forefront of quantum-safe solutions, safeguarding the future of cybersecurity. Our experts are not only engaged in pioneering quantum computing-resistant solutions but are also driving the search for the most robust algorithms to ensure the security of our customers and society's communications once again. As we join hands with the NIST PQC Migration Consortium, we embark on a journey to shape a quantum-secure world for generations to come," finishes TeemuTunkelo, CEO of SSH Communications Security.
Additional information on this Consortium can be found at: https://www.nccoe.nist.gov/projects/building-blocks/post-quantum-cryptography
Read more about SSH’s Quantum-Safe Cryptographic Security Solutions: Quantum Safe Cryptography (QSC) Security Solutions | SSH
For further information, please contact:
Teemu Tunkelo, CEO, tel. +358 40 5499605, email Teemu.Tunkelo@ssh.com
Suvi Lampila, SSH Fellow, email Suvi.Lampila@ssh.com
SSH helps organizations safeguard their mission-critical digital assets at rest, in transit, and in use. We have 5,000+ customers worldwide, including 40 percent of Fortune 500 companies and major organizations in the Finance, Government, Retail, and Industrial segment. We are committed to helping our customers secure their business in the age of hybrid cloud and distributed IT and OT solutions. Our Zero Trust solutions offer safe electronic communications and secure access to servers and between servers. Our teams in North America, Europe, and Asia, along with a global network of certified partners, ensure customer success. The company’s shares (SSH1V) are listed on Nasdaq Helsinki. www.ssh.com.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote
Monument Reports Fourth Quarter and Fiscal 2023 Results29.9.2023 21:26:28 CEST | Press release
Gross Revenue of US$12.39 Million and Cash Cost of US$917/Oz for Gold Sulphide Production and US$1,622/Oz for Gold Oxide Production VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2023. All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results). Cathy Zhai, the President and CEO commented, “Fiscal 2023 was a milestone year for the Company with the gold sulphide project completed, and the flotation plant was put into production at the Selinsing Gold Mine in Malaysia. The commercial production has also been reached in August 2023 subsequent to the year end. It again demonstrates Monument has been able to deliver what’s been promised and now we are ready for the next corporate move.” Fiscal Year 2023 Highlights: Construction of the Selinsing sulphide flotation pla
Nokia Corporation: Repurchase of own shares on 29.09.202329.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 29 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.09.2023 Espoo, Finland – On 29 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL319,5513.57CEUX58,3773.57AQEU11,0113.57TQEX4,7613.57Total393,7003.57 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
EPH European Property Holdings PLC announces Unaudited Interim Results for the Six Months to 30 June 2023 and appointment of Management Committee Members29.9.2023 19:00:00 CEST | Press release
29 September 2023, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS FIRST HALF YEAR OF 2023 With an established portfolio of high-quality properties in prime locations in Europe occupied by tenants with strong credit ratings, combined with professional asset management, EPH European Property Holdings PLC (“EPH” or the “Company”) has demon-strated operational stability in the first six months of 2023, despite the ongoing market environment challenges. As a result, EPH not only achieved almost full occupancy throughout its European portfolio, it also increased rental income.The sale of the Company’s Russian portfolio was concluded in April 2023, following the Extraordinary General Meeting (held on 1 November 2022) at which the shareholders of EPH authorised the Board of Directors to sell EPH Group’s entire Russian property portfolio by way of a management buyout. Upon disposal of the Russian segment in the first half of 2023, the Company reclassified the
Oxurion Publishes First Half 2023 Results29.9.2023 19:00:00 CEST | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US –September 29, 2023 – 7.00PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel